Cubist
Executive Summary
IND application filed for daptomycin for bacteremia and skin and soft tissue infections Jan. 1, CEO Scott Rocklage, PhD, reported Jan. 12. The company has completed a Phase II trial in skin and soft tissue infections, and is currently conducting Phase II studies for the bacteremia indication. Cubist expects to file NDAs for both indications by the end of 2000. FDA has said that it will designate the product for a "fast track" review